Literature DB >> 17004724

Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.

David Rennison1, Humphrey Moynihan, John R Traynor, John W Lewis, Stephen M Husbands.   

Abstract

The 14-aminodihydromorphinone and codeinone series of opioid ligands have produced a number of ligands of substantial interest. To investigate the importance of the 14-substituent, a series of analogues in which the side chain length is varied and the amide and alkene functions are reduced have been prepared. Binding affinity, particularly at the mu-opioid receptor (MOR), was largely determined by the aromatic group of the side chain. In the [35S]GTPgammaS functional assay, the ligands having a three-carbon side chain were more potent antagonists than their longer chain counterparts, while shorter, two-carbon chain analogues were of higher MOR efficacy, an effect that was confirmed in vivo. Wash-resistant binding was observed within this series and appeared to be unrelated to side-chain length.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004724      PMCID: PMC2538686          DOI: 10.1021/jm060595u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Chemoenzymatic Synthesis of Isotopically Labeled Chorismic Acids.

Authors:  Darin J. Gustin; Donald Hilvert
Journal:  J Org Chem       Date:  1999-06-25       Impact factor: 4.354

Review 2.  Pharmacotherapy of addictions.

Authors:  Mary Jeanne Kreek; K Steven LaForge; Eduardo Butelman
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

3.  Dependence studies on new compounds in the rhesus monkey, rat and mouse (1989).

Authors:  M D Aceto; E R Bowman; L S Harris; E L May
Journal:  NIDA Res Monogr       Date:  1989

Review 4.  Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse.

Authors:  J H Woods; J W Lewis; G Winger; E Butelman; J Broadbear; G Zernig
Journal:  NIDA Res Monogr       Date:  1995

5.  New 14-aminomorphinones and codeinones.

Authors:  J Lewis; C Smith; P McCarthy; D Walter; R Kobylecki; M Myers; A Haynes; C Lewis; K Waltham
Journal:  NIDA Res Monogr       Date:  1988

6.  Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus.

Authors:  C Chavkin; A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.

Authors:  I Derrick; C L Neilan; J Andes; S M Husbands; J H Woods; J R Traynor; J W Lewis
Journal:  J Med Chem       Date:  2000-08-24       Impact factor: 7.446

Review 8.  Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse.

Authors:  Stephen M Husbands; John W Lewis
Journal:  Mini Rev Med Chem       Date:  2003-03       Impact factor: 3.862

9.  14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity.

Authors:  A Sebastian; J M Bidlack; Q Jiang; D Deecher; M Teitler; S D Glick; S Archer
Journal:  J Med Chem       Date:  1993-10-15       Impact factor: 7.446

10.  Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

Authors:  J R Traynor; S R Nahorski
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

View more
  11 in total

1.  14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.

Authors:  Guo Li; Lindsey C K Aschenbach; Hengjun He; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2008-12-29       Impact factor: 2.823

2.  14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.

Authors:  Nick P R Nieland; David Rennison; Jillian H Broadbear; Lauren Purington; James H Woods; John R Traynor; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

3.  Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.

Authors:  Nick P R Nieland; Humphrey A Moynihan; Simon Carrington; Jillian Broadbear; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

4.  Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.

Authors:  David Rennison; Adrian P Neal; Gerta Cami-Kobeci; Mario D Aceto; Fernando Martinez-Bermejo; John W Lewis; Stephen M Husbands
Journal:  J Med Chem       Date:  2007-09-22       Impact factor: 7.446

5.  Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

Authors:  Yan Zhang; Orgil Elbegdorj; Yunyun Yuan; Irina O Beletskaya; Dana E Selley
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

6.  Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.

Authors:  Gerta Cami-Kobeci; Adrian P Neal; Faye A Bradbury; Lauren C Purington; Mario D Aceto; Louis S Harris; John W Lewis; John R Traynor; Stephen M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

7.  14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.

Authors:  H Moynihan; A R Jales; B M Greedy; D Rennison; J H Broadbear; L Purington; J R Traynor; J H Woods; J W Lewis; S M Husbands
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

8.  Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.

Authors:  Mariana Spetea; Petra Windisch; Yan Guo; Indre Bileviciute-Ljungar; Johannes Schütz; Muhammad Faheem Asim; Ilona P Berzetei-Gurske; Pal Riba; Kornel Kiraly; Susanna Fürst; Mahmoud Al-Khrasani; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2011-01-14       Impact factor: 7.446

9.  Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.

Authors:  Humphrey A Moynihan; Ian Derrick; Jillian H Broadbear; Benjamin M Greedy; Mario D Aceto; Louis S Harris; Lauren C S Purington; Mark P Thomas; James H Woods; John R Traynor; Stephen M Husbands; John W Lewis
Journal:  J Med Chem       Date:  2012-10-31       Impact factor: 7.446

10.  μ Opioid receptor: novel antagonists and structural modeling.

Authors:  Teresa Kaserer; Aquilino Lantero; Helmut Schmidhammer; Mariana Spetea; Daniela Schuster
Journal:  Sci Rep       Date:  2016-02-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.